Orchid Biosciences Chairman George Poste was named to the Monsanto board of directors, the company said recently. Poste replaces Philip Needleman, chief scientific officer and senior vice president of Pharmacia.
Poste is also CEO of Health Technology Networks, a consultancy in genomics and health-care computing. He was formerly CSO, CTO, and president of R&D for SmithKline Beecham. He is a member of the defense science board of the Department of Defense and is the chairman of the group’s task force on bioterrorism.
Steve McPhail has been named CEO of Expression Analysis, the microarray analysis firm said last week. He replaces Donald Holzworth, president and CEO of Analytical Sciences, who has acted as EA’s interim CEO since September 2001 when ASI began incubating the company. Holzworth will now serve as chairman of EA’s board.
McPhail joins the Durham, NC-based company from a stint at medical device manufacturer ArgoMed where he served as executive vice president and COO. Prior to joining ArgoMed, McPhail held senior-level sales, marketing, and business-development positions at Xanthon, TriPath Imaging, Dynex Technologies and Abbott Laboratories.
Greg Schiffman, chief financial officer for Affymetrix, has been named to the board of directors of Impac Medical Systems of Mountain View, Calif., the company said last week.
Meanwhile, Schiffman’s former colleague Ed Hurwitz has resigned as interim chief executive officer of Aclara Biosciences. The one-time CFO of Affymetrix turned in notice on Feb. 21, saying he was leaving to concentrate full-time on his job as venture partner for Alta Partners, a San Francisco venture capital firm.
The company’s board has brought back Joseph Limber, who stepped down as CEO December 1, to manage the company as part of “the office of the president” along with director Andre Marion. Hurwitz will continue to serve on the board of Aclara, which is focusing on development of its eTag assays.